US2300311063 - Common Stock
CULLINAN THERAPEUTICS INC
NASDAQ:CGEM (5/16/2024, 9:38:44 AM)
25.775
-0.95 (-3.54%)
Cullinan Oncology, Inc. is a biopharmaceutical company engaged in developing oncology and immuno-oncology therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 62 full-time employees. The company went IPO on 2021-01-08. The firm is focused on creating standards of care for patients with cancer. The Company’s lead candidate, Zipalertinib (CLN-081/TAS6417) in a Phase IIb, is an orally available small molecule designed as an irreversible epidermal growth factor receptor (EGFR), inhibitor that is designed to selectively target cells expressing mutant EGFR variants, including EGFR exon 20 insertion (EGFRex20ins), mutations, with relative sparing of cells expressing wild type EGFR. The Company’s evaluating CLN-081 as a treatment for non-small cell lung cancer (NSCLC), in adult patients with EGFRex20ins mutations in a Phase IIb trial. The Company’s other product candidates include CLN-049, CLN-619, CLN-418, CLN-617 and CLN-978. Its CLN-049 is a FLT3/CD3 T cell engaging bispecific antibody being investigated in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
CULLINAN THERAPEUTICS INC
One Main Street, Suite 1350
Cambridge MASSACHUSETTS 02142
P: 16174104650
CEO: Owen Hughes
Employees: 62
Website: https://www.cullinanoncology.com/
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cullinan Oncology (NASDAQ:CGEM) just reported results for the first quarter of ...
CGEM stock results show that Cullinan Oncology beat analyst estimates for earnings per share the first quarter of 2024.
Combination and monotherapy solid tumor dose escalation data for CLN-619 to be presented in a poster session at ASCO 2024 Annual Meeting CLN-978...
Here you can normally see the latest stock twits on CGEM, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: